|
|
|
|
Incannex Healthcare Inc (NASDAQ: IXHL) |
|
Price: $1.9300
$0.08 
4.324%
|
| Day's High:
| $1.93
| Week Perf:
| 7.22 %
|
| Day's Low: |
$ 1.85 |
30 Day Perf: |
1.58 % |
| Volume (M): |
20 |
52 Wk High: |
$ 8.47 |
| Volume (M$): |
$ 39 |
52 Wk Avg: |
$2.61 |
| Open: |
$1.85 |
52 Wk Low: |
$1.50 |
|
|
| Market Capitalization (Millions $) |
31 |
| Shares
Outstanding (Millions) |
16 |
| Employees |
11 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-5 |
| Cash Flow (TTM) (Millions $) |
-32 |
| Capital Exp. (TTM) (Millions $) |
1 |
Incannex Healthcare Inc
Company Address: Suite 105 NSW 2153
Company Phone Number: 409 840 786 Stock Exchange / Ticker: NASDAQ IXHL
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Financing Agreement
Published Tue, Sep 10 2024 12:00 PM UTC
In the fast-evolving landscape of biotech and pharmaceuticals, securing adequate funding is often the linchpin for advancing innovative therapies and sustaining growth. Recently, Incannex Healthcare, a company focused on the development of therapies utilizing psychedelic compounds, announced a significant strategic financing agreement that could reshape its financial tr...
|
| Clinical Study
Published Mon, Aug 5 2024 11:30 AM UTC
FDA Approves Incannex Healthcare?s Phase 2 Clinical Trial for Psilocybin-Assisted Psychotherapy in Generalized Anxiety Disorder Patients In an exciting development for the field of psychiatric and psychedelic-assisted therapies, Incannex Healthcare Inc. (Nasdaq: IXHL) has received approval from the US Food and Drug Administration (FDA) to proceed with an Investigational Ne...
|
| Clinical Study
Published Tue, Jul 30 2024 11:30 AM UTC
Incannex Healthcare Advances Novel Therapeutics for Sleep Apnea and Rheumatoid Arthritis: Completion of Dosing in Bioavailability Trial and Launch of Phase 2 Study for IHL-675A Incannex Healthcare Inc., a clinical-stage pharmaceutical company at the forefront of developing innovative medicinal cannabinoid products and psychedelic-assisted therapies, has made significant st...
|
| Clinical Study
Published Thu, May 30 2024 11:30 AM UTC
Patient Dosing Commenced in RePOSA Phase 2/3 Clinical Trial to Evaluate the Efficacy of IHL-42X Drug in Patients with Obstructive Sleep ApneaObstructive Sleep Apnea (OSA) is a common sleep disorder that affects millions of people worldwide. It is characterized by repeated episodes of partial or complete obstruction of the upper airway during sleep, leading to disrupted breat...
|
| Product Service News
Published Tue, May 7 2024 11:30 AM UTC
In a significant step forward in the battle against the opioid epidemic, Incannex Healthcare Inc., a leading cannabinoid and psychedelic medicine biotechnology company, has successfully completed a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA). The meeting s was to gain FDA approval for the development of CannQuit-O, a potential...
|
| Per Share |
Current |
| Earnings (TTM) |
-0.3 $ |
| Revenues (TTM) |
0 $
|
| Cash Flow (TTM) |
- |
| Cash |
0.36 $
|
| Book Value |
0.7 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.3 $
|
| Revenues (TTM) |
0 $ |
| Cash Flow (TTM) |
- |
| Cash |
0.36 $
|
| Book Value |
0.7 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
0.58%